Press release summary
Amprion highlighted peer-reviewed research showing that a skin-based alpha-synuclein seed-amplification assay can distinguish multiple system atrophy from neuronal synuclein diseases, including Parkinsonโs disease and dementia with Lewy bodies. The study was published in npj Parkinsonโs Disease.
The researchers reported agreement between skin and cerebrospinal-fluid testing, including concordance among samples from patients with prodromal Parkinsonโs disease and dementia with Lewy bodies. Skin-assay positivity also increased as Parkinsonโs disease progressed. Amprionโs currently available SAAmplify-ฮฑSYN Plus laboratory-developed test uses cerebrospinal fluid; the skin assay remains a research-use method that the company plans to advance toward clinical commercialization.
Why it matters for laboratories
A validated skin-biopsy method could provide a more accessible specimen pathway than lumbar puncture for detecting misfolded alpha-synuclein and differentiating related neurodegenerative disorders. It may also expand biomarker options for clinical trials and patient stratification. The research is an important feasibility step, but laboratories still need standardized collection procedures, multicenter reproducibility data, defined clinical cutoffs and regulatory validation before routine diagnostic adoption.
Original source: Amprionโs Oct. 5, 2026, announcement. The underlying study is available from npj Parkinsonโs Disease.






Leave a Reply